Haemonetics Historical Income Statement

HAE Stock

USD 90.75 1.03 1.12%

Historical analysis of Haemonetics income statement accounts such as Gross Profit of 710.4 M or Operating Income of 173.1 M can show how well Haemonetics performed in making a profits. Evaluating Haemonetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Haemonetics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Haemonetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Haemonetics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

About Haemonetics Income Statement Analysis

Haemonetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Haemonetics shareholders. The income statement also shows Haemonetics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Haemonetics Income Statement Chart

At present, Haemonetics' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 710.4 M, whereas Other Operating Expenses is forecasted to decline to about 566.7 M.

Total Revenue Gross Profit Ebitda Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Haemonetics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Haemonetics minus its cost of goods sold. It is profit before Haemonetics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Haemonetics. It is also known as Haemonetics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Haemonetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 710.4 M, whereas Other Operating Expenses is forecasted to decline to about 566.7 M.

	2021	2022	2023	2024 (projected)
Gross Profit	505.5M	615.1M	676.5M	710.4M
Total Revenue	993.2M	1.2B	1.3B	1.4B

Gross Profit Total Revenue

Haemonetics income statement Correlations

	Interest Expense	Total Revenue	Gross Profit	Operating Income	Ebit	Ebitda	Depreciation And Amortization	Other Operating Expenses	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Extraordinary Items	Net Income From Continuing Ops	Non Operating Income Net Other	Selling And Marketing Expenses	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Interest Expense		0.03	0.04	0.0	-0.37	-0.39	-0.18	0.06	0.0	0.07	0.18	0.18	0.18	0.18	0.16	0.07	-0.3	0.09	0.15	0.12	-0.3	-0.16	0.02	0.02	-0.09
Total Revenue	0.03		0.96	0.17	0.33	0.6	0.62	0.53	0.71	0.7	0.55	-0.15	0.52	0.39	0.57	0.73	-0.69	0.28	-0.59	0.37	-0.05	0.69	0.42	-0.42	0.05
Gross Profit	0.04	0.96		0.4	0.52	0.72	0.45	0.35	0.55	0.61	0.69	-0.06	0.66	0.52	0.53	0.65	-0.51	0.47	-0.59	0.55	-0.24	0.8	0.52	-0.49	0.0
Operating Income	0.0	0.17	0.4		0.85	0.73	-0.24	-0.42	-0.25	-0.22	0.85	0.31	0.83	0.63	-0.27	-0.14	0.39	0.94	-0.19	0.67	-0.55	0.66	0.51	-0.48	0.19
Ebit	-0.37	0.33	0.52	0.85		0.93	-0.1	-0.32	-0.13	-0.17	0.69	-0.02	0.66	0.5	-0.25	-0.05	0.38	0.75	-0.33	0.61	-0.25	0.76	0.52	-0.49	0.11
Ebitda	-0.39	0.6	0.72	0.73	0.93		0.23	-0.04	0.18	0.1	0.71	-0.15	0.68	0.5	-0.06	0.21	0.06	0.67	-0.52	0.56	-0.12	0.84	0.59	-0.58	0.23
Depreciation And Amortization	-0.18	0.62	0.45	-0.24	-0.1	0.23		0.77	0.93	0.8	0.04	-0.37	0.05	0.07	0.52	0.77	-0.78	-0.19	-0.53	0.01	0.39	0.21	0.28	-0.32	0.57
Other Operating Expenses	0.06	0.53	0.35	-0.42	-0.32	-0.04	0.77		0.82	0.74	-0.1	-0.21	-0.1	0.0	0.63	0.74	-0.74	-0.33	-0.31	-0.15	0.26	0.05	0.12	-0.06	0.31
Cost Of Revenue	0.0	0.71	0.55	-0.25	-0.13	0.18	0.93	0.82		0.91	0.12	-0.26	0.13	0.19	0.71	0.91	-0.83	-0.14	-0.45	0.17	0.26	0.25	0.25	-0.22	0.41
Total Operating Expenses	0.07	0.7	0.61	-0.22	-0.17	0.1	0.8	0.74	0.91		0.15	-0.11	0.15	0.25	0.89	0.95	-0.8	-0.1	-0.48	0.27	-0.01	0.26	0.29	-0.24	0.22
Income Before Tax	0.18	0.55	0.69	0.85	0.69	0.71	0.04	-0.1	0.12	0.15		0.43	0.99	0.7	0.05	0.21	-0.07	0.94	-0.3	0.66	-0.6	0.76	0.55	-0.53	0.08
Total Other Income Expense Net	0.18	-0.15	-0.06	0.31	-0.02	-0.15	-0.37	-0.21	-0.26	-0.11	0.43		0.46	0.21	-0.01	-0.18	0.19	0.52	0.27	0.09	-0.73	0.04	-0.06	0.08	-0.31
Net Income	0.18	0.52	0.66	0.83	0.66	0.68	0.05	-0.1	0.13	0.15	0.99	0.46		0.59	0.02	0.2	-0.09	0.95	-0.34	0.59	-0.61	0.68	0.58	-0.57	0.07
Income Tax Expense	0.18	0.39	0.52	0.63	0.5	0.5	0.07	0.0	0.19	0.25	0.7	0.21	0.59		0.27	0.28	-0.02	0.57	0.01	0.84	-0.35	0.78	0.26	-0.16	0.3
Research Development	0.16	0.57	0.53	-0.27	-0.25	-0.06	0.52	0.63	0.71	0.89	0.05	-0.01	0.02	0.27		0.81	-0.64	-0.18	-0.28	0.33	-0.15	0.18	0.07	0.04	0.0
Selling General Administrative	0.07	0.73	0.65	-0.14	-0.05	0.21	0.77	0.74	0.91	0.95	0.21	-0.18	0.2	0.28	0.81		-0.74	-0.03	-0.42	0.3	0.07	0.36	0.28	-0.2	0.27
Extraordinary Items	-0.3	-0.69	-0.51	0.39	0.38	0.06	-0.78	-0.74	-0.83	-0.8	-0.07	0.19	-0.09	-0.02	-0.64	-0.74		0.23	0.35	0.1	-0.21	-0.07	-0.1	0.15	-0.15
Net Income From Continuing Ops	0.09	0.28	0.47	0.94	0.75	0.67	-0.19	-0.33	-0.14	-0.1	0.94	0.52	0.95	0.57	-0.18	-0.03	0.23		-0.22	0.6	-0.67	0.62	0.53	-0.51	0.04
Non Operating Income Net Other	0.15	-0.59	-0.59	-0.19	-0.33	-0.52	-0.53	-0.31	-0.45	-0.48	-0.3	0.27	-0.34	0.01	-0.28	-0.42	0.35	-0.22		-0.22	0.17	-0.31	-0.84	0.86	-0.23
Selling And Marketing Expenses	0.12	0.37	0.55	0.67	0.61	0.56	0.01	-0.15	0.17	0.27	0.66	0.09	0.59	0.84	0.33	0.3	0.1	0.6	-0.22		-0.41	0.69	0.43	-0.29	0.22
Non Recurring	-0.3	-0.05	-0.24	-0.55	-0.25	-0.12	0.39	0.26	0.26	-0.01	-0.6	-0.73	-0.61	-0.35	-0.15	0.07	-0.21	-0.67	0.17	-0.41		-0.21	-0.4	0.33	0.31
Tax Provision	-0.16	0.69	0.8	0.66	0.76	0.84	0.21	0.05	0.25	0.26	0.76	0.04	0.68	0.78	0.18	0.36	-0.07	0.62	-0.31	0.69	-0.21		0.4	-0.38	0.17
Interest Income	0.02	0.42	0.52	0.51	0.52	0.59	0.28	0.12	0.25	0.29	0.55	-0.06	0.58	0.26	0.07	0.28	-0.1	0.53	-0.84	0.43	-0.4	0.4		-0.96	0.25
Net Interest Income	0.02	-0.42	-0.49	-0.48	-0.49	-0.58	-0.32	-0.06	-0.22	-0.24	-0.53	0.08	-0.57	-0.16	0.04	-0.2	0.15	-0.51	0.86	-0.29	0.33	-0.38	-0.96		-0.25
Reconciled Depreciation	-0.09	0.05	0.0	0.19	0.11	0.23	0.57	0.31	0.41	0.22	0.08	-0.31	0.07	0.3	0.0	0.27	-0.15	0.04	-0.23	0.22	0.31	0.17	0.25	-0.25

Click cells to compare fundamentals

Haemonetics Account Relationship Matchups

Haemonetics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	16.2M	16.8M	17.1M	14.6M	13.0M	15.4M
Total Revenue	988.5M	870.5M	993.2M	1.2B	1.3B	1.4B
Gross Profit	484.5M	397.8M	505.5M	615.1M	676.5M	710.4M
Operating Income	154.0M	58.0M	80.8M	156.0M	164.9M	173.1M
Ebit	154.0M	58.0M	71.7M	156.0M	208.1M	218.5M
Ebitda	264.2M	142.3M	169.5M	249.3M	305.4M	320.6M
Depreciation And Amortization	110.3M	84.3M	97.7M	93.3M	97.2M	54.3M
Other Operating Expenses	834.5M	812.5M	921.5M	459.1M	1.1B	566.7M
Cost Of Revenue	504.0M	472.6M	487.7M	553.6M	632.5M	330.3M
Total Operating Expenses	330.6M	339.9M	433.8M	459.1M	468.4M	254.8M
Income Before Tax	87.2M	72.9M	63.6M	141.4M	151.9M	159.5M
Total Other Income Expense Net	(66.8M)	15.0M	(17.1M)	(14.6M)	(13.0M)	(13.7M)
Net Income	76.5M	79.5M	43.4M	115.4M	117.6M	123.4M
Income Tax Expense	10.6M	(6.6M)	20.3M	26.0M	34.3M	17.5M
Research Development	30.9M	32.9M	46.8M	50.1M	54.4M	33.3M
Selling General Administrative	295.4M	271.5M	335.2M	369.5M	424.7M	235.5M
Net Income Applicable To Common Shares	76.5M	79.5M	43.4M	115.4M	132.7M	139.3M
Net Income From Continuing Ops	76.5M	79.5M	43.4M	115.4M	117.6M	123.4M
Non Operating Income Net Other	(16.2M)	(16.8M)	(17.1M)	(14.6M)	(13.2M)	(13.8M)
Selling And Marketing Expenses	4.3M	2.7M	4.4M	7.2M	7.1M	4.8M
Tax Provision	10.6M	(6.6M)	20.3M	26.0M	34.3M	36.0M
Interest Income	16.2M	16.8M	17.1M	14.6M	16.8M	13.3M
Net Interest Income	(16.2M)	(16.8M)	(17.1M)	(14.6M)	(13.0M)	(13.7M)
Reconciled Depreciation	110.3M	84.3M	97.7M	93.3M	97.2M	77.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.375

Earnings Share

2.39

Revenue Per Share

26.77

Quarterly Revenue Growth

0.086

Return On Assets

0.0588

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Historical Income Statement

About Haemonetics Income Statement Analysis

Haemonetics Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Haemonetics income statement Correlations

Haemonetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Haemonetics income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 0.99	Income Before Tax
Gross Profit	+ 0.96	Total Revenue
Selling General Administrative	+ 0.95	Total Operating Expenses
Net Income From Continuing Ops	+ 0.95	Net Income
Net Income From Continuing Ops	+ 0.94	Operating Income
Net Income From Continuing Ops	+ 0.94	Income Before Tax

Net Interest Income	- 0.96	Interest Income
Interest Income	- 0.84	Non Operating Income Net Other
Extraordinary Items	- 0.83	Cost Of Revenue
Extraordinary Items	- 0.8	Total Operating Expenses
Extraordinary Items	- 0.78	Depreciation And Amortization
Extraordinary Items	- 0.74	Selling General Administrative